- Home
- GNS vs ACRS Comparison
GNS vs ACRS Comparison
Compare GNS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- ACRS
- Stock Information
- Founded
- GNS 2002
- ACRS 2012
- Country
- GNS Singapore
- ACRS United States
- Employees
- GNS N/A
- ACRS N/A
- Industry
- GNS Other Consumer Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- GNS Real Estate
- ACRS Health Care
- Exchange
- GNS Nasdaq
- ACRS Nasdaq
- Market Cap
- GNS 138.7M
- ACRS 165.7M
- IPO Year
- GNS 2022
- ACRS 2015
- Fundamental
- Price
- GNS $0.99
- ACRS $1.68
- Analyst Decision
- GNS
- ACRS Strong Buy
- Analyst Count
- GNS 0
- ACRS 9
- Target Price
- GNS N/A
- ACRS $9.25
- AVG Volume (30 Days)
- GNS 9.1M
- ACRS 710.1K
- Earning Date
- GNS 04-30-2025
- ACRS 08-06-2025
- Dividend Yield
- GNS N/A
- ACRS N/A
- EPS Growth
- GNS N/A
- ACRS N/A
- EPS
- GNS N/A
- ACRS N/A
- Revenue
- GNS $7,912,718.00
- ACRS $17,777,000.00
- Revenue This Year
- GNS $233.65
- ACRS N/A
- Revenue Next Year
- GNS $570.20
- ACRS $8.11
- P/E Ratio
- GNS N/A
- ACRS N/A
- Revenue Growth
- GNS N/A
- ACRS N/A
- 52 Week Low
- GNS $0.21
- ACRS $1.05
- 52 Week High
- GNS $2.37
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- GNS 45.02
- ACRS 62.53
- Support Level
- GNS $1.06
- ACRS $1.51
- Resistance Level
- GNS $1.26
- ACRS $1.78
- Average True Range (ATR)
- GNS 0.24
- ACRS 0.09
- MACD
- GNS -0.08
- ACRS 0.01
- Stochastic Oscillator
- GNS 5.56
- ACRS 70.59
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.